A Phase 1 study of JY231 injection in relapsed/refractory neurologic immune disorders
Recruiting Not Applicable NCT06797024
Study Description
A study to evaluate the safety and effectiveness of a new cell therapy (JY231 injection) in patients with relapsed or treatment-resistant neurological immune disorders
Study Details
- Registry ID:
- NCT06797024
- Conditions:
- Autoimmune Diseases of the Nervous System
- Phase:
- Not Applicable
- Target Enrollment:
- 20 participants
- Start Date:
- Age Range:
- 18–75 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.